Examining cutaneous disease activity as an outcome measure for clinical trials in dermatomyositis - 16/05/19
Doi : 10.1016/j.jaad.2019.01.028
Rebecca G. Gaffney, BA a, b, Rui Feng, PhD c, David R. Pearson, MD a, b, Meera Tarazi, BA a, b, Victoria P. Werth, MD a, b, ⁎ 
a Corporal Michael J. Crescenz VAMC, Philadelphia, Pennsylvania
b Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
c Department of Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania
∗Reprint requests: Victoria P. Werth, MD, Department of Dermatology, Perelman Center for Advanced Medicine, Ste 1-330A, 3400 Civic Center Blvd, Philadelphia, PA 19104Department of DermatologyPerelman Center for Advanced MedicineSte 1-330A3400 Civic Center BlvdPhiladelphiaPA19104
| Funding sources: Supported by the U.S. Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development and Biomedical Laboratory Research and Development). The funding sponsor was not involved. |
|
| Conflicts of interest: None disclosed. |
|
| Previous presented at the International Investigative Dermatology Meeting in May 2018 in Orlando, Florida. |
© 2019
Publié par Elsevier Masson SAS.
Vol 80 - N° 6
P. 1793-1794 - juin 2019 Retour au numéro
Article précédent
- The acceleration of melanoma in situ: A population-based study of melanoma incidence trends from Victoria, Australia, 1985-2015
- David J. Curchin, Emily Forward, Philippa Dickison, Victoria R. Harris, Chris J. McCormack, Saxon D. Smith
- Keratoacanthomas: A review of excised specimens
- Mitchell Gibbons, Alexander Ernst, Ashaki Patel, Eric Armbrecht, Ramona Behshad
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?